[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631804":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":23,"collaborators":7,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":7,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":7,"studyType":40,"phases":7,"briefSummary":41,"conditions":42,"keywords":45,"overallStatus":55,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":7},{"fullName":5,"class":6},"Assiut University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","verapamil","Intervention Name: Verapamil Other Names: Verapamil hydrochloride Clinical specimens from cancer patients collected for routine testing will be included. Bacterial isolates will be cultured on appropriate media and identified using standard microbiological methods and\u002For automated systems. Antimicrobial susceptibility testing will be performed using the Kirby-Bauer disk diffusion method or automated systems according to CLSI 2025 guidelines.\n\nA stock solution of verapamil will be prepared under aseptic conditions. The antibacterial activity of selected antibiotics alone and in combination with verapamil will be evaluated. Minimum inhibitory concentrations (MICs) will be determined using the broth microdilution method. Synergistic interactions will be assessed using the checkerboard method and quantified by fractional inhibitory concentration index (FICI).",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Ahmed I Khalaf Mohamed, Demonstrator","CONTACT","+201144427816","drahmednafady0794@gmail.com",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Enas A Daef, professor","+201223971411","Deafenas@yahoo.com",{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Ahmed Ibrahim Khalaf Mohamed","Demonstrator of Cancer Biology, South Egypt Cancer Institute, Assiut University","100631804","characterization-of-the-synergistic-antibacterial-effect-of-verapamil-on-bacterial-isolates-from-cancer-patients-100631804",false,"NCT07505446","Characterization of the Synergistic Antibacterial Effect of Verapamil on Bacterial Isolates From Cancer Patients","Characterization of the Synergistic Antibacterial Effect of Verapamil on Bacterial Isolates From Patients in South Egypt Cancer Institute","Inclusion Criteria:\n\n1. Bacterial isolates from clinical samples submitted for the SECI laboratory for culture and sensitivity testing that are:\n2. MDR: resistant to one or more agent within three or more of antimicrobial classes\n3. XDR: resistant to one or more agent within all but two antimicrobial classes\n4. PDR: resistant to all agents within all antimicrobial classes.\n\nExclusion Criteria:\n\n1. Bacterial isolates from non-cancer patients.\n2. Contaminant or non-pathogenic isolates.\n3. Duplicate isolates from the same patient with identical antibiogram.\n4. Bacterial isolates that are neither MDR, XDR OR PDR.","ALL","18 Years","90 Years",{"count":38,"type":39},100,"ESTIMATED","OBSERVATIONAL","Multidrug-resistant (MDR) bacteria represent a significant global health challenge, particularly among immunocompromised populations such as cancer patients undergoing chemotherapy. These patients are highly susceptible to severe infections due to weakened immune defenses, often necessitating the use of broad-spectrum or combination antibiotic therapy. Combination regimens may enhance treatment efficacy through synergistic effects, helping to overcome bacterial resistance mechanisms and improve clinical outcomes.\n\nIn recent years, there has been growing interest in the use of non-antibiotic drugs as adjunctive agents to enhance antimicrobial activity. These agents, often referred to as antibiotic adjuvants or resistance modifiers, may improve antibiotic effectiveness through mechanisms such as inhibition of bacterial efflux pumps, disruption of biofilm formation, or interference with resistance pathways.\n\nVerapamil, a widely used calcium channel blocker, has demonstrated potential antimicrobial and resistance-modifying properties. Experimental evidence suggests that verapamil can inhibit bacterial efflux pumps, thereby increasing intracellular concentrations of antibiotics and enhancing their activity against resistant organisms.\n\nThis study aims to evaluate the in vitro synergistic antibacterial activity of verapamil in combination with selected antibiotics against MDR, extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacterial isolates obtained from cancer patients. Standard microbiological methods will be used to determine antimicrobial susceptibility and minimum inhibitory concentrations, while combination effects will be assessed using established synergy testing approaches.\n\nThe findings of this study may contribute to identifying novel, cost-effective strategies to combat antimicrobial resistance through drug repurposing and optimization of existing antibiotic therapies.",[43,44],"Multi Drug Resistant Organisms","Antibiotic Resistance",[46,47,48,49,50,51,52,53,54],"Verapamil","Antibiotic Adjuvant","Efflux Pump Inhibitor","Antimicrobial Synergy","Checkerboard Assay","Fractional Inhibitory Concentration Index (FICI)","Minimum Inhibitory Concentration (MIC)","MDR \u002F XDR \u002F PDR Bacteria","Cancer Patient Isolates","NOT_YET_RECRUITING","2026-04-02",{"date":58,"type":59},"2026-04-08","ACTUAL",{"date":61,"type":39},"2026-05-01",{"date":63,"type":39},"2027-06-01",{"name":5,"class":6}]